Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Purpose: To review significant advances in the early diagnosis and treatment of medullary thyroid carcinoma in patients with the multiple endocrine neoplasia II (MEN II) syndromes, advances made possible by the application of recently discovered genetic information. Data Sources: Recently published English-language literature on linkage analysis and DNA analysis in the MEN II syndromes. Study Selection: Articles on familial and sporadic forms of medullary thyroid carcinoma; pentagastrin-calcitonin determination; and genetic testing. Data Extraction: Information from recent studies on 1) the usefulness and limitations of genetic testing, especially DNA and linkage analysis, in the early diagnosis of the familial form of thyroid carcinoma and 2) the correlation between the results of genetic testing and the results of biochemical screening. Data Synthesis: Medullary thyroid carcinoma accounts for most of the morbidity and mortality among patients with the familial medullary thyroid carcinoma syndromes. Multiple endocrine neoplasia IIa and IIb and familial medullary thyroid carcinoma are inherited conditions with autosomal dominance and incomplete penetrance. Traditionally, diagnosis of and screening for these conditions have been done using pentagastrin stimulation tests and plasma calcitonin determinations. Recent genetic mapping, however, has assigned the genes responsible for these tumors to the pericentromeric region of chromosome 10. Available data suggest that mutations in exon 10, 11, or 16 of the RET protooncogene are responsible for MEN IIa and IIb and familial non-MEN medullary thyroid carcinoma. Thus, genetic testing can identify affected members of a kindred and will probably lead to early thyroidectomy and possible cure for gene carriers. Conclusions: Early studies confirm the usefulness of DNA analysis in the diagnosis and treatment of patients with familial forms of medullary thyroid carcinoma. We review changes in the diagnosis and treatment of these patients and offer a strategy for operative intervention based on results of genetic testing.

Original languageEnglish (US)
Pages (from-to)118-124
Number of pages7
JournalAnnals of Internal Medicine
Volume122
Issue number2
StatePublished - 1995

Fingerprint

Multiple Endocrine Neoplasia
Genetic Testing
Pentagastrin
Information Storage and Retrieval
Calcitonin
Early Diagnosis
DNA
Multiple Endocrine Neoplasia Type 2b
Multiple Endocrine Neoplasia Type 2a
Chromosomes, Human, Pair 10
Penetrance
Thyroidectomy
Thyroid Neoplasms
Genes
Exons
Language
Therapeutics
Morbidity
Mutation
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. / Ledger, G. A.; Khosla, Sundeep; Lindor, Noralane Morey; Thibodeau, Stephen N; Gharib, H.

In: Annals of Internal Medicine, Vol. 122, No. 2, 1995, p. 118-124.

Research output: Contribution to journalArticle

@article{a0a2d3bb08524889a260f18242148ee9,
title = "Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II",
abstract = "Purpose: To review significant advances in the early diagnosis and treatment of medullary thyroid carcinoma in patients with the multiple endocrine neoplasia II (MEN II) syndromes, advances made possible by the application of recently discovered genetic information. Data Sources: Recently published English-language literature on linkage analysis and DNA analysis in the MEN II syndromes. Study Selection: Articles on familial and sporadic forms of medullary thyroid carcinoma; pentagastrin-calcitonin determination; and genetic testing. Data Extraction: Information from recent studies on 1) the usefulness and limitations of genetic testing, especially DNA and linkage analysis, in the early diagnosis of the familial form of thyroid carcinoma and 2) the correlation between the results of genetic testing and the results of biochemical screening. Data Synthesis: Medullary thyroid carcinoma accounts for most of the morbidity and mortality among patients with the familial medullary thyroid carcinoma syndromes. Multiple endocrine neoplasia IIa and IIb and familial medullary thyroid carcinoma are inherited conditions with autosomal dominance and incomplete penetrance. Traditionally, diagnosis of and screening for these conditions have been done using pentagastrin stimulation tests and plasma calcitonin determinations. Recent genetic mapping, however, has assigned the genes responsible for these tumors to the pericentromeric region of chromosome 10. Available data suggest that mutations in exon 10, 11, or 16 of the RET protooncogene are responsible for MEN IIa and IIb and familial non-MEN medullary thyroid carcinoma. Thus, genetic testing can identify affected members of a kindred and will probably lead to early thyroidectomy and possible cure for gene carriers. Conclusions: Early studies confirm the usefulness of DNA analysis in the diagnosis and treatment of patients with familial forms of medullary thyroid carcinoma. We review changes in the diagnosis and treatment of these patients and offer a strategy for operative intervention based on results of genetic testing.",
author = "Ledger, {G. A.} and Sundeep Khosla and Lindor, {Noralane Morey} and Thibodeau, {Stephen N} and H. Gharib",
year = "1995",
language = "English (US)",
volume = "122",
pages = "118--124",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II

AU - Ledger, G. A.

AU - Khosla, Sundeep

AU - Lindor, Noralane Morey

AU - Thibodeau, Stephen N

AU - Gharib, H.

PY - 1995

Y1 - 1995

N2 - Purpose: To review significant advances in the early diagnosis and treatment of medullary thyroid carcinoma in patients with the multiple endocrine neoplasia II (MEN II) syndromes, advances made possible by the application of recently discovered genetic information. Data Sources: Recently published English-language literature on linkage analysis and DNA analysis in the MEN II syndromes. Study Selection: Articles on familial and sporadic forms of medullary thyroid carcinoma; pentagastrin-calcitonin determination; and genetic testing. Data Extraction: Information from recent studies on 1) the usefulness and limitations of genetic testing, especially DNA and linkage analysis, in the early diagnosis of the familial form of thyroid carcinoma and 2) the correlation between the results of genetic testing and the results of biochemical screening. Data Synthesis: Medullary thyroid carcinoma accounts for most of the morbidity and mortality among patients with the familial medullary thyroid carcinoma syndromes. Multiple endocrine neoplasia IIa and IIb and familial medullary thyroid carcinoma are inherited conditions with autosomal dominance and incomplete penetrance. Traditionally, diagnosis of and screening for these conditions have been done using pentagastrin stimulation tests and plasma calcitonin determinations. Recent genetic mapping, however, has assigned the genes responsible for these tumors to the pericentromeric region of chromosome 10. Available data suggest that mutations in exon 10, 11, or 16 of the RET protooncogene are responsible for MEN IIa and IIb and familial non-MEN medullary thyroid carcinoma. Thus, genetic testing can identify affected members of a kindred and will probably lead to early thyroidectomy and possible cure for gene carriers. Conclusions: Early studies confirm the usefulness of DNA analysis in the diagnosis and treatment of patients with familial forms of medullary thyroid carcinoma. We review changes in the diagnosis and treatment of these patients and offer a strategy for operative intervention based on results of genetic testing.

AB - Purpose: To review significant advances in the early diagnosis and treatment of medullary thyroid carcinoma in patients with the multiple endocrine neoplasia II (MEN II) syndromes, advances made possible by the application of recently discovered genetic information. Data Sources: Recently published English-language literature on linkage analysis and DNA analysis in the MEN II syndromes. Study Selection: Articles on familial and sporadic forms of medullary thyroid carcinoma; pentagastrin-calcitonin determination; and genetic testing. Data Extraction: Information from recent studies on 1) the usefulness and limitations of genetic testing, especially DNA and linkage analysis, in the early diagnosis of the familial form of thyroid carcinoma and 2) the correlation between the results of genetic testing and the results of biochemical screening. Data Synthesis: Medullary thyroid carcinoma accounts for most of the morbidity and mortality among patients with the familial medullary thyroid carcinoma syndromes. Multiple endocrine neoplasia IIa and IIb and familial medullary thyroid carcinoma are inherited conditions with autosomal dominance and incomplete penetrance. Traditionally, diagnosis of and screening for these conditions have been done using pentagastrin stimulation tests and plasma calcitonin determinations. Recent genetic mapping, however, has assigned the genes responsible for these tumors to the pericentromeric region of chromosome 10. Available data suggest that mutations in exon 10, 11, or 16 of the RET protooncogene are responsible for MEN IIa and IIb and familial non-MEN medullary thyroid carcinoma. Thus, genetic testing can identify affected members of a kindred and will probably lead to early thyroidectomy and possible cure for gene carriers. Conclusions: Early studies confirm the usefulness of DNA analysis in the diagnosis and treatment of patients with familial forms of medullary thyroid carcinoma. We review changes in the diagnosis and treatment of these patients and offer a strategy for operative intervention based on results of genetic testing.

UR - http://www.scopus.com/inward/record.url?scp=0028851141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028851141&partnerID=8YFLogxK

M3 - Article

C2 - 7992986

AN - SCOPUS:0028851141

VL - 122

SP - 118

EP - 124

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -